Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

White House Medicare Rx Draft Proposes “Enhanced” Fee For Service Option

Executive Summary

The Bush Administration is considering an "enhanced" fee-for-service Medicare program that would offer a prescription drug benefit for seniors beginning in 2006

You may also be interested in...



Medicare Rx Funding Will Exceed $400 Bil., Breaux Predicts; War No Obstacle

Senate Medicare Rx legislation is likely to exceed the $400 bil. in funding set aside for the program by President Bush, Sen. John Breaux (D-La.) told the Pharmaceutical Research & Manufacturers of America annual meeting March 28 in Naples, Fla

Medicare Rx Funding Will Exceed $400 Bil., Breaux Predicts; War No Obstacle

Senate Medicare Rx legislation is likely to exceed the $400 bil. in funding set aside for the program by President Bush, Sen. John Breaux (D-La.) told the Pharmaceutical Research & Manufacturers of America annual meeting March 28 in Naples, Fla

Medicare Rx Hinges On Senate Finance Cmte.; White House Delays Details

The prospects for a Medicare drug benefit in 2003 are likely to hinge on the ability of the Senate Finance Committee to find a bipartisan consensus over the next several months

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel